

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/109363 A1

(51) International Patent Classification:

A61K 31/554 (2006.01) C07D 515/20 (2006.01)
A61P 31/20 (2006.01)

(21) International Application Number:

PCT/US2021/060247

(22) International Filing Date:

22 November 2021 (22.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/117,170 23 November 2020 (23.11.2020) US
63/142,663 28 January 2021 (28.01.2021) US
17/479,244 20 September 2021 (20.09.2021) US
17/479,530 20 September 2021 (20.09.2021) US

(71) Applicant: ENANTA PHARMACEUTICALS, INC.

[US/US]; 500 Arsenal Street, Watertown, MA 02472 (US).

(72) Inventors: WANG, Guoqiang; 65 Becket Road, Belmont, MA 02478 (US). SHEN, Ruichao; 151 Dean St, Belmont, MA 02478 (US). HE, Yong; 34 Calvin Street, Lexington, MA 02420 (US). MA, Jun; 7 Richard Road, Wayland, MA 01778 (US). XING, Xuechao; 20 Cedar Street, Wilmington, MA 01887 (US). CAO, Hui; 49 Thayer Rd, Belmont, MA 02478 (US). GAO, Xuri; 15 Walker Street, Newtonville, MA 02460 (US). PENG, Xiaowen; 85 Horse Pond Road, Sudbury, MA 01776 (US). LONG, Jiang; 15 Wallace Road, Wayland, MA 01778 (US). LI, Wei; 64 Prospect Hill Rd, Lexington, MA 02421 (US). ZHANG, Jiajun; 42 Maple Ave, #2, Cambridge, MA 02139 (US). PANARESE, Joseph, D.; 441 Lowell Avenue, Newton, MA 02460 (US). KENTON, Nathaniel, Thomas; 764 Mount Auburn Street, Watertown, MA 02472 (US). BARTLETT, Samuel; 410 Market Street, Apartment 4, Brighton, MA 02135 (US). OR, Yat, Sun; 29 Michaelchris Drive, Waltham, MA 02452 (US).

(74) Agent: HARLAN, Edgar, W. et al.; Elmore Patent Law Group, P.C., 484 Groton Road, Westford, MA 01886 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,


HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS



(Ia)

(57) Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: Formula (Ia) which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.



WO 2022/109363 A1